Evgen Pharma Share Discussion Threads

[muddy_40] 06/5/2021 19:52

Should maybe add the John Hopkins publication. And mention that write up. That's not really promotion I would think?

[bumpa33] 06/5/2021 19:32

Hmm, someone didn’t like my (wikipedia) sulforaphane update.


Please do not add promotional material to Wikipedia, as you did to Sulforaphane. While objective prose about beliefs, organisations, people, products or services is acceptable, Wikipedia is not a vehicle for soapboxing, advertising or promotion. Thank you. Zefr (talk) 14:51, 6 May 2021 (UTC)

[moneymunch] 06/5/2021 17:57

Molecules Review

Potential of Sulforaphane as a Natural Immune System Enhancer:

.................

During the last year, the world has been shocked by the abrupt irruption of COVID-19 and the scientific community has been devoted to find insights that help fight against this disease.

A way to reduce the severity and mortality generated by acute respiratory distress syndrome (ARDS) produced by SARS-COV 2 is to strengthen the immune system.

ARDS produces a dysregulation of the immunological system, and in the most severe cases, the release of pro-inflammatory cytokines and loss of T-cells in the infected organism [52].

There is evidence of the antiviral effect of Nrf2 on respiratory syncytial virus infection [53]and on SARS-COV 1 [54].

Based on information about viruses that belong to the same family, it has been proposed that compounds that activate Nrf2 could probably help to diminish these effects.

Cuadrado et al. [55] suggested that due to its ability to activate Nrf2, induce antioxidant enzymes, reduce pro-inflammatory cytokines, and its efficacy and safety, SFN is a promising candidate to counteract inflammatory reaction and protect lungs from severe damage during SARS COV 2 infection.

Finally, Horowitz and Freeman [56]suggested that clinical trials including administration of Nrf2-activating molecules, such as Molecules of SFN, are imperative to support a possible three-party strategy to fight the COVID-19 pandemic, which includes prevention, diagnostic, and treatment.

[bumpa33] 06/5/2021 10:53

If you google sulforaphane the second top hit is Wikipedia. I’ve edited the ‘Research’ section to bring it up to speed.

[moneymunch] 06/5/2021 10:35

Nice one Bumpa, it's quite amazing how much evidence is out there that points to the undoubted potential of SFX-01 for treating Covid/ARDS etc, yet despite efficacy results expected imminently, it seems to be completely under the radar, unkown and/or disregarded by mainstream commentators who highlight potential treatments or how difficult it is or will be in finding potential treatments.....hopefully Prof Chalmers and Huw will enlighten them very soon on SFX-01's positive therapeutic efficacy. Gl ;-)

[muddy_40] 06/5/2021 10:25

Good find Bumpa33. And all papers saying the same. Let's hope they have the efficacy, and Prof Chalmers and the new CMO are designing the rest of the trial and maybe in conjunction with other treatments to be ready for the autumn and a result for Boris's taskforce..

[bumpa33] 06/5/2021 10:00

Another day, another research paper...






”Conclusion
We have developed a simple experimental system and analytical protocol for the screening of molecules interfering with the expression of proteins known to be involved in the COVID-19 “cytokine storm”. The results here presented demonstrate that exposure of epithelial IB3-1 cells to the SARS-CoV-2 spike protein induces increased expression of NF-κB and increased release particularly of IL-6 and IL-8, but also of IL-9, FGF, G-CSF, GM-CSF, MCP-1 and MIP-1β. This allows the screening of possible inhibitors of these biochemical targets and possible agents to be proposed for the experimental treatment of this clinical phase of the disease.

Treatment with sulforaphane reverses IL-6 and IL-8 upregulation induced by SARS-CoV-2 Spike protein in IB3-1 cells. Furthermore, sulforaphane-mediated inhibitory effects were observed also for PDGF, IL-9, G-CSF, GM-CSF, IFN-γ, MCP-1 and MIP-1β. Therefore, sulforaphane and sulforaphane-containing phytoproducts should be further evaluated as potential inhibitors of the COVID-19 “cytokine storm”.

Further experiments should be programmed to identify other agents able to inhibit changes in gene expression induced by SARS-CoV-2 Spike, not only to identify novel molecules to be considered as positive control in this experimental system, but also to verify whether combined therapy with sulforaphane is possible”

[peanut100] 06/5/2021 07:34

Now for EVG also

[bumpa33] 06/5/2021 07:17

I see this morning AVCT have dumped Finncap... (no comment)

[bocker01] 06/5/2021 07:09

Agreed Money! Very limited and short term downside and massive upside! Some great research being posted too.

[moneymunch] 05/5/2021 22:14

Lol bocker, fortune favours the brave, but in this instance it looks like a no brainer, every chance of positive efficacy data from the Covid/Ards trial given the compelling research on Sulforaphane from John Hopkins and a raft of other Scientific publications that suggests our chances couldn't look better, otherwise a raft of other potential material news from the rest of the pipeline that must be stacking up...this is a very rare opportunity for incredible upside if all goes to plan....and not long to go before we know...Gl.:-)

Ps a drop of 40% on bad news would take us down to the c£13m cash in the bank and so i would be surprised if it fell below the cash level...and so good news on the current clinical breast cancer programme, the US IND application, etc etc would see the share price recover in no time imho....On and UP!!!:-)

[bocker01] 05/5/2021 21:35

This will halve on the day on ARDS bad news or increase immediately by factor 5 on good. With a factor 2-4 to follow on only one subsequent deal in negotiation RNS. Probabilities favour good. Love this seat of the pants stuff! When the breast stuff means you’ll get your halving restored in 12 months and no loss just future gains its kind of weird.

[moneymunch] 05/5/2021 18:47

Good point On Target, if Prof Chalmers assessment wasn't looking good, I'm sure that Evgen would want it out of the way as soon as possible so that Huw could start updating the market on the rest of the pipeline to temper any disappointment, and so the fact we're still waiting is a good sign imho, especially following on from John Hopkins research and the timing of Boris's ambitious Autumn home pill target....Tick Tock..:-)))

[on target] 05/5/2021 18:22

By my calculations they are now in the 6th week of the efficacy assessment, so clearly they have something meaningful to assess. Looking forward to some news on this front soon. Fingers crossed!

[moneymunch] 05/5/2021 18:19

Everything firmly crossed PDT for good news from Prof Chalmers...if efficacy is confirmed and SFX-01 has similar effects highlighted by John Hopkins University compelling research on Sulforaphane's therapuetic benefits in treating Covid, several variants, ARDS, pneumonia etc and more importantly, preventing the onset of Covid/Ards etc, then there is every chance that SFX-01 will be prime candidate for Boris's Autumn home pill target and Evgen's market cap and share price will no doubt be many multiples of current bargain low.....Exciting times for all invested....news from Prof Chalmers at anytime and also a raft of other news stacking UP from Huw on the rest of the pipeline, all of which could add further significant value.....Bring it on!!! ;-)

[pdt] 05/5/2021 17:08

Moneymunch - thanks for that article.

It is interesting that Eli Lilly's JAK inhibitor Olumiant got an EUA in the US. It also reduces STAT3. However, it's efficacy was weak. It does demonstrate that the bar is quite low for SFX01 to be a success.



As you say the advantage SFX01 has is that it also has the NRF2 pathway as was well as STAT3 suppression. You would hope with the two combined it could get a better result than Lilly's Olumiant (which has just been given an EUA in India).

[moneymunch] 05/5/2021 16:15

Yes indeed PDT, as well as SFX-01's potency over Nrf2 for Covid/Ards, its influence over STAT3 could also be of significance in proving efficacy. Gl ;-)




Contribution of STAT3 to the pathogenesis of COVID-19

Highlights

STAT-3 can be activated by numerous cytokines during COVID-19.

STAT-3 is hyper-activated and can play a central role in COVID-19 pathogenesis.

Activated STAT-3 can promote hyper-inflammation, lung fibrosis and thrombosis.

Activated STAT-3 promotes lymphopenia and impairs anti-virus immune responses.

STAT3 may be a potential therapeutic target for the treatment of COVID-19.

[pdt] 05/5/2021 15:18

New research just out implicates excess STAT3 as partly responsible for the cytokine storm and poor outcomes. SFX01 has been shown to reduce STAT3.



"Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis"

FLIP-expressing myeloid cells are key drivers of CRS through aberrant overexpression of STAT3 pathway. STAT3-targeting is effective in mitigating CRS like severe COVID-19.

[moneymunch] 05/5/2021 12:06

A nice big late reported 945k buy from yesterday....all bodes well. Gla ;-)

[muddy_40] 05/5/2021 12:02

Bumpa33.

I think so also, I thought here the oncology was the main thing for treatment and hopefully still is, ARDs covid could easy be the icing on the cake, With that small trail and the John Hopkins publication.

We must have news soon on the Covid and something on the new cancer study what Huw is excited about.

Let's hope it is good.

[moneymunch] 05/5/2021 11:59

Firmly in our favour Bumpa imho....and hopefully not long now before we find out. Gl ;-)

[bumpa33] 05/5/2021 09:23

“experimental clinical cases represent a proof-of-concept CONFIRMING(!) the hypothesis that Nrf2-interacting nutrients are effective in COVID-19. However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety.”



I do find it incredible that we don’t have more interest here - yet. We have a mini version of a trial as described with these 3 cases showing efficacy. There are no guarantees (for our initial 100 patients) of course but surely the odds here are pretty bloody good?

[bumpa33] 05/5/2021 09:16

“The most potent Nrf2 natural activator is sulforaphane,4, 5, 6, 7, 8, 9, 10 but it is difficult to deliver in an enriched and stable form for purposes of direct human consumption.11 Thus, glucoraphanin, the precursor of sulforaphane, is administered orally with myrosinase, the enzyme that transforms glucoraphanin into sulforaphane.


They should’ve used SFX-01. This is why what we have is such a potential game changer.

[muddy_40] 05/5/2021 08:43

I was thinking about this report PDT posted about a week ago. After taking the medication it showed a near immediate improvement. Did they see in clinical trials that some patients showed a big improvement near immediate, and this may be main reason to the unblinding after 100 patients knowing the urgency to get remedies..

Food for thought as they say..

The patient increased the dosage of the broccoli capsules on day 3. The first dose of 600 mg of broccoli (4 capsules) (7:00) improved the symptoms incompletely, and he therefore took a higher dose 5 h later (900 mg). Interestingly, the ingestion of the capsules always induced the same effect with rapid disappearance of cough, nasal obstruction, nausea and diarrhea, improvement in fatigue, and some reduction in fever

[pdt] 05/5/2021 07:43

Posted this morning by Markinvestor on the SNG thread;

"The European Commission will propose the joint procurement of Covid-19 treatments, as it seeks to secure supplies of potentially critical drugs for the period past the acute phase of the pandemic, according to a document seen by Bloomberg.

The plan by the European Union’s executive arm sets out the need for a common European framework for the development and deployment of targeted therapeutics for coronavirus patients and aims to avoid a patchwork of policies across the 27-nation bloc. The commission is due to adopt the proposal on Wednesday and unveil it on Thursday.

Securing the supply of such treatments will limit the need for hospitalization, speed up recovery times and ultimately save lives of citizens across the bloc, the commission says in the draft of the plan seen by Bloomberg. Its aim is to have three new therapeutics available by October 2021 and possibly two more by year-end"

My Comment - if EVG can show efficacy and they can get the manufacturing in place as mentioned at the fundraise then they could receive large stockpile orders for future pandemics or new waves. I had not considered the stockpile demand angle.